Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19094370 | SOLID STATE CRYSTALLINE FORMS OF A SELECTIVE POTASSIUM CHANNEL MODULATOR | March 2025 | April 2025 | Allow | 1 | 0 | 0 | Yes | No |
| 19024709 | USE OF REBOXETINE TO TREAT NARCOLEPSY | January 2025 | March 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 18958628 | MALATE SALT OF N-(4-{[6,7-BIS(METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCER | November 2024 | February 2025 | Allow | 3 | 1 | 0 | No | No |
| 18945079 | TREATMENT OF MIGRAINE | November 2024 | June 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18924415 | TREATMENT OF MIGRAINE | October 2024 | March 2025 | Allow | 5 | 1 | 0 | No | No |
| 18919625 | DOSING REGIMEN FOR INJECTABLE CETIRIZINE | October 2024 | February 2025 | Allow | 4 | 1 | 0 | No | No |
| 18889824 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF MIGRAINE | September 2024 | December 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18776516 | TREATMENT OF MIGRAINE | July 2024 | November 2024 | Allow | 4 | 0 | 1 | Yes | No |
| 18764612 | COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES | July 2024 | May 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18745768 | PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | June 2024 | June 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18741969 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | June 2024 | January 2025 | Allow | 7 | 0 | 0 | Yes | No |
| 18670680 | USING ADIPONECTIN RECEPTOR AGONISTS TO TREAT INFLAMMATION AND BONE DISEASES IN DIABETES | May 2024 | May 2025 | Allow | 12 | 2 | 0 | Yes | No |
| 18663025 | TREATMENT OF MIGRAINE | May 2024 | July 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18644733 | Methods Of Treating Parkinson�s Disease and/or Lewy Body Disease or Disorder(s) | April 2024 | May 2025 | Abandon | 12 | 1 | 0 | Yes | No |
| 18642707 | PIPERIDINE COMPOUNDS AS PDE5 INHIBITORS | April 2024 | July 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18637529 | CRYSTAL FORM OF QUINOLINE COMPOUND AND PROCESS FOR ITS PRODUCTION | April 2024 | May 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18692452 | APPLICATION OF PTGDS INHIBITOR IN PREPARATION OF DRUG FOR TREATING CATARACTS | March 2024 | July 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18604727 | METHODS AND USES FOR TREATING ANHEDONIA | March 2024 | October 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18593308 | TREATMENT OF MIGRAINE | March 2024 | October 2024 | Allow | 7 | 1 | 0 | No | No |
| 18440217 | TREATMENT OF MIGRAINE | February 2024 | December 2024 | Abandon | 10 | 1 | 1 | No | No |
| 18433099 | SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF | February 2024 | March 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18423824 | Method of Treating Cancer | January 2024 | February 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18393515 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | December 2023 | July 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18389771 | USE OF REBOXETINE TO TREAT NARCOLEPSY | December 2023 | October 2024 | Allow | 10 | 0 | 0 | No | No |
| 18544621 | APPLICATION OF Z-LIGUSTILIDE IN RESISTING ROTAVIRUSES | December 2023 | March 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18533755 | PIPERIDINE-2,6-DIONE DERIVATIVES AND ULCERATIVE COLITIS TREATING | December 2023 | February 2025 | Allow | 14 | 1 | 0 | No | No |
| 18526220 | Multi-Aziridine Compound | December 2023 | July 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18524426 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | November 2023 | February 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18523481 | TREATMENT OF MIGRAINE | November 2023 | February 2024 | Allow | 2 | 0 | 0 | No | No |
| 18520986 | 2-ETHOXY-8-(4-FLUOROBENZYLIDENE)-4-(4-FLUOROPHENYL)-5,6,7,8-TETRAHYDROQUINOLINE-3-CARBONITRILE AS AN ANTIMICROBIAL COMPOUND | November 2023 | February 2024 | Allow | 3 | 0 | 0 | No | No |
| 18519782 | METHODS OF TREATING KIDNEY CONDITIONS USING MODIFIED FORMS OF TRIMETAZIDINE | November 2023 | December 2024 | Allow | 13 | 1 | 0 | No | No |
| 18508798 | 6-(3-HYDROXYPHENYL)-2-METHOXY-4-(3-METHYLPHENYL)NICOTINONITRILE AS AN ANTIMICROBIAL COMPOUND | November 2023 | February 2024 | Allow | 3 | 0 | 0 | No | No |
| 18388618 | FORMULATION, USE AND METHOD FOR BROAD-SPECTRUM PROPHYLAXIS AND TREATMENT OF VIRAL INFECTIONS CAUSED BY SARS-COV-2 AND OTHER EMERGENT VIRUSES | November 2023 | October 2024 | Allow | 11 | 1 | 0 | No | No |
| 18388299 | KCNQ POTENTIATORS | November 2023 | February 2025 | Allow | 15 | 1 | 0 | Yes | No |
| 18504741 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | November 2023 | October 2024 | Allow | 11 | 0 | 1 | No | No |
| 18501481 | GRISEOFULVIN COMPOUND | November 2023 | May 2024 | Allow | 7 | 0 | 0 | No | No |
| 18386443 | 4,4'-NAPHTHALENE-1,5-DIYLBIS(DIAZENE-2,1-DIYL)DINAPHTHALEN-1-OL AS AN ANTIOXIDANT COMPOUND | November 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18386185 | 6'-(3-BROMOPHENYL)-2'-ETHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS AN ANTIOXIDANT COMPOUND | November 2023 | January 2024 | Allow | 2 | 0 | 0 | No | No |
| 18497225 | 4,4'-NAPHTHALENE-1,5-DIYLBIS(DIAZENE-2,1-DIYL)DIBENZENE-1,2-DIOL AS AN ANTIOXIDANT COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18383629 | ETHYL 4-(5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)BUTANOATE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18492723 | 1-(2-(SUBSTITUTED PHENYL)-2-OXOETHYL)-3,5-DIMETHYLPYRIDIN-1-IUM BROMIDES AS ANTITUBERCULAR AGENTS | October 2023 | January 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18488912 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | October 2023 | December 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18378750 | N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2- YLTHIO)ACETOXY)-3,4-DIMETHOXYBENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18484722 | SOLID FORMS | October 2023 | June 2024 | Allow | 9 | 0 | 0 | Yes | No |
| 18377542 | 1-2(-(SUBSTITUTED PHENYL)-2-OXOETHYL)-4-(ISOPROPOXYCARBONYL)PYRIDIN-1-IUM BROMIDES AS ANTI-TUBERCULAR AGENTS | October 2023 | December 2023 | Allow | 3 | 0 | 0 | No | No |
| 18377407 | 1-(2-(SUBSTITUTED PHENYL)-2-OXOETHYL)-4-METHYLPYRIDIN-1-IUM BROMIDE AS ANTI-TUBERCULAR AGENTS | October 2023 | November 2024 | Allow | 13 | 2 | 0 | Yes | No |
| 18369857 | SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | September 2023 | September 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18367889 | 3-(1-(3-(DIMETHYLAMINO)PROPYL)-4,5-DIPHENYL-1H-IMIDAZOL-2-YL)PYRIDIN-4-OL AS AN ANTI-MICROBIAL COMPOUND | September 2023 | November 2023 | Allow | 2 | 0 | 0 | No | No |
| 18240256 | SUBSTITUTED 7-METHYL QUINOLINE DERIVATIVES AS ANTITUBERCULAR AGENTS | August 2023 | December 2023 | Allow | 3 | 1 | 0 | No | No |
| 18239978 | SUBSTITUTED CYCLIC AMIDES AND THEIR USE AS HERBICIDES | August 2023 | May 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18237211 | ETHYL 2-SUBSTITUTED-1-(SUBSTITUTEDBENZOYL)-7-METHYLPYRROLO[1,2-a]QUINOLINE-3-CARBOXYLATE DERIVATIVES AS ANTI-TUBERCULAR AGENTS | August 2023 | October 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18454711 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | August 2023 | March 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18236207 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | August 2023 | September 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18229825 | SUBSTITUTED PHENYL QUINOLIN-1-IUM BROMIDE DERIVATIVE AS ANTITUBERCULAR AGENTS | August 2023 | November 2023 | Allow | 4 | 1 | 0 | No | No |
| 18228593 | METHOD OF TREATMENT OF SYMPTOMS OF MENOPAUSE | July 2023 | October 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18362073 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | July 2023 | March 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18225930 | DOSING OF CV-10155 IN THE EVENING OR PRIOR TO SLEEP TO TREAT GABAA DISORDERS | July 2023 | January 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18355194 | IRAK DEGRADERS AND USES THEREOF | July 2023 | October 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18221902 | METHOD FOR PREPARING PYRIDINE COMPOUND SUBSTITUTED WITH TRIFLUOROMETHYLTHIO, DIFLUOROMETHYLTHIO OR TRIFLUOROMETHYL IN META POSITION | July 2023 | October 2023 | Allow | 3 | 0 | 0 | No | No |
| 18348198 | NEUROPROTECTIVE COMPOUNDS FOR AMYOTROPHIC LATERAL SCLEROSIS | July 2023 | October 2024 | Allow | 15 | 0 | 0 | Yes | No |
| 18343197 | METHODS FOR THE TREATMENT OF DYSKINESIA IN CEREBRAL PALSY | June 2023 | March 2025 | Allow | 20 | 2 | 0 | Yes | No |
| 18213601 | COMBINATION OF ZIBOTENTAN AND DAPAGLIFLOZIN FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES | June 2023 | April 2024 | Allow | 10 | 1 | 0 | No | No |
| 18212337 | CRYSTAL FORMS OF 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE | June 2023 | April 2024 | Allow | 10 | 0 | 0 | Yes | No |
| 18210719 | TREATMENT OF MIGRAINE | June 2023 | August 2023 | Allow | 2 | 0 | 0 | No | No |
| 18334683 | CRYSTAL FORM OF QUINOLINE COMPOUND AND PROCESS FOR ITS PRODUCTION | June 2023 | July 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18144979 | Therapeutic Uses of Relacorilant, a Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulator | May 2023 | April 2024 | Allow | 11 | 0 | 0 | Yes | No |
| 18305529 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | April 2023 | March 2024 | Allow | 11 | 0 | 0 | No | No |
| 18299266 | USING ADIPONECTIN RECEPTOR AGONISTS TO TREAT INFLAMMATION AND BONE DISEASES IN DIABETES | April 2023 | June 2024 | Allow | 14 | 2 | 0 | No | No |
| 18132244 | METHOD OF TREATING TRYPANOSOMIASIS | April 2023 | August 2023 | Allow | 5 | 1 | 0 | No | No |
| 18127726 | Salt of Cabozantinib | March 2023 | July 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 18183281 | Compounds for the Treatment Of Acute and Chronic Kidney Disease | March 2023 | November 2023 | Allow | 8 | 0 | 0 | Yes | No |
| 18112214 | Method of Treating Cancer | February 2023 | February 2024 | Allow | 12 | 1 | 0 | Yes | No |
| 18170384 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | February 2023 | November 2023 | Allow | 9 | 0 | 0 | Yes | No |
| 18040456 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | February 2023 | July 2025 | Allow | 29 | 0 | 0 | Yes | No |
| 18006330 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | January 2023 | June 2024 | Allow | 17 | 0 | 1 | Yes | No |
| 18156333 | SLC26A3 INHIBITORS AND USE THEREOF | January 2023 | July 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 18097046 | METHOD OF TREATMENT OF SYMPTOMS OF MENOPAUSE | January 2023 | April 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18096548 | 3-SUBSTITUTED QUINOLIN-2-ONE COMPOUNDS AS ANTIBACTERIAL AGENTS | January 2023 | April 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18152375 | COMPOUNDS AND METHODS FOR TREATING ALCOHOL DISORDER | January 2023 | June 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18150870 | ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | January 2023 | February 2025 | Allow | 60 | 1 | 0 | No | No |
| 18149590 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | January 2023 | April 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 18146785 | AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS | December 2022 | June 2023 | Allow | 6 | 0 | 0 | Yes | No |
| 18084866 | Therapeutic Uses of Relacorilant, a Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulator | December 2022 | April 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 18065636 | METHOD FOR PREPARATION OF TRANS-N-BENZYLOXYCARBONYL-(3-HYDROXY-2-PIPERIDINYL)-2-PROPANONE AS INTERMEDIATE OF HALOFUGINONE | December 2022 | June 2025 | Allow | 30 | 0 | 0 | No | No |
| 18008871 | COMPOUND USEFUL AS TOLL-LIKE RECEPTOR 7 ACTIVATION INHIBITOR | December 2022 | June 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18000685 | CRYSTAL FORM OF 2-METHYL-2-PROPANOL AND AMINO-SUBSTITUTED ARYL COMPOUND | December 2022 | May 2023 | Allow | 5 | 0 | 0 | No | No |
| 18057511 | COMPOUND HAVING CYCLIC STRUCTURE | November 2022 | January 2025 | Allow | 26 | 1 | 1 | Yes | No |
| 17925449 | FLUORINE-CONTAINING FUSED RING PYRIMIDINE COMPOUND AND METHOD FOR PRODUCING SAME | November 2022 | June 2025 | Allow | 31 | 0 | 0 | No | No |
| 17986419 | CRYSTAL FORMS OF 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE | November 2022 | April 2023 | Allow | 5 | 0 | 0 | Yes | No |
| 18055095 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | November 2022 | July 2024 | Abandon | 20 | 0 | 1 | No | No |
| 18054435 | CDK9 Inhibitors and Polymorphs Thereof For Use As Agents For Treatment of Cancer | November 2022 | April 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 17998018 | INTERMEDIATES AND SYNTHESIS FOR ENDOCHIN-LIKE QUINOLONE COMPOUNDS | November 2022 | June 2025 | Allow | 31 | 0 | 0 | No | No |
| 18052268 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | November 2022 | April 2023 | Allow | 6 | 0 | 0 | Yes | No |
| 18051953 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | November 2022 | May 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17922208 | Processes for the Preparation of a Kinase Inhibitor | October 2022 | June 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 17997324 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | October 2022 | May 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 17921610 | CRYSTALS, PREPARATION METHOD AND APPLICATION OF A MUSCARINIC RECEPTOR ANTAGONIST | October 2022 | June 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 17996886 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | October 2022 | May 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18046270 | GRISEOFULVIN COMPOUND | October 2022 | July 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 17914063 | PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF | September 2022 | May 2025 | Allow | 32 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ROZOF, TIMOTHY R.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ROZOF, TIMOTHY R works in Art Unit 1625 and has examined 1,718 patent applications in our dataset. With an allowance rate of 82.5%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 16 months.
Examiner ROZOF, TIMOTHY R's allowance rate of 82.5% places them in the 49% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by ROZOF, TIMOTHY R receive 0.77 office actions before reaching final disposition. This places the examiner in the 7% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by ROZOF, TIMOTHY R is 16 months. This places the examiner in the 97% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +23.4% benefit to allowance rate for applications examined by ROZOF, TIMOTHY R. This interview benefit is in the 73% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 42.5% of applications are subsequently allowed. This success rate is in the 93% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 50.3% of cases where such amendments are filed. This entry rate is in the 71% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 92.3% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 83.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 64.3% are granted (fully or in part). This grant rate is in the 81% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.8% of allowed cases (in the 64% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.1% of allowed cases (in the 45% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.